Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | PRCP | P42785 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16223451 | 1.00 | KCNH2 (0.45) | KCNH2CYP3A4PRCPCYP2C9PREP | |
| SCHEMBL1478082 | 0.94 | KCNH2 (0.42) | KCNH2CYP3A4PRCPCYP2C9PREP | |
| SCHEMBL1477978 | 0.94 | KCNH2 (0.41) | KCNH2CYP3A4PRCPCYP2C9PREP | |
| SCHEMBL1477983 | 0.94 | KCNH2 (0.41) | KCNH2CYP3A4PRCPCYP2C9PREP | |
| SCHEMBL1478074 | 0.94 | KCNH2 (0.42) | KCNH2CYP3A4PRCPCYP2C9PREP | |
| SCHEMBL1479453 | 0.94 | PRCP (0.43) | KCNH2PRCPPPIBPPIAADAM17 | |
| SCHEMBL1479444 | 0.94 | PRCP (0.43) | KCNH2PRCPPPIBPPIAADAM17 | |
| SCHEMBL1478695 | 0.92 | KCNH2 (0.42) | KCNH2CYP3A4PRCPCYP2C9PPIB | |
| SCHEMBL1478981 | 0.91 | KCNH2 (0.42) | KCNH2CYP3A4PRCPCYP2C9PPIB | |
| SCHEMBL883039 | 0.91 | KCNH2 (0.58) | KCNH2CYP3A4PRCPCYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414350-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-12 | — | — | EP | claimed |
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-01 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | KCNH2 4814/4885CYP3A4 3387/4885PRCP 573/4885 |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | KCNH2 4814/4885CYP3A4 3387/4885PRCP 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.